Lisata Therapeutics Statistics
Lisata Therapeutics (0HS8) Stock Statistics & Valuation Metrics
Total Valuation
Lisata Therapeutics has a market cap or net worth of $11.02M. The enterprise value is $20.26M.
- Market Cap
- $11.02M
- Enterprise Value
- $20.26M
Share Statistics
Lisata Therapeutics has 10,804,066 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,804,066
- Owned by Insiders
- 8.81%
- Owned by Institutions
- 6.33%
Financial Efficiency
Lisata Therapeutics’s return on equity (ROE) is -1.12 and return on invested capital (ROIC) is -117.30%.
- Return on Equity (ROE)
- -1.12
- Return on Assets (ROA)
- -0.93
- Return on Invested Capital (ROIC)
- -117.30%
- Return on Capital Employed (ROCE)
- -1.24
- Revenue Per Employee
- 8,095.238
- Profits Per Employee
- -789.81K
- Employee Count
- 21
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lisata Therapeutics is -0.73. Lisata Therapeutics’s PEG ratio is -0.02.
- PE Ratio
- -0.73
- PS Ratio
- 108.13
- PB Ratio
- 1.33
- Price to FCF
- -0.88
- Price to Operating Cash Flow
- -0.89
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 170.00K and earned -16.59M in profits. Earnings per share was -1.91.
- Revenue
- 170.00K
- Gross Profit
- 24.00K
- Operating Income
- -18.21M
- Pretax Income
- -17.55M
- Net Income
- -16.59M
- EBITDA
- -17.40M
- Earnings Per Share (EPS)
- -1.91
Cash Flow
In the last 12 months, operating cash flow was -12.32M and capital expenditures 0, giving a free cash flow of -12.32M billion.
- Operating Cash Flow
- -12.32M
- Free Cash Flow
- -12.32M
- Free Cash Flow per Share
- -1.35
Dividends & Yields
Lisata Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -113.96%
- Earnings Yield
- -133.80%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- -43.68%
- 50-Day Moving Average
- 1.33
- 200-Day Moving Average
- 2.93
- Relative Strength Index (RSI)
- 52.49
- Average Volume (3m)
- 4,931
Important Dates
Lisata Therapeutics upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Lisata Therapeutics as a current ratio of 5.76, with Debt / Equity ratio of 0.00%
- Current Ratio
- 5.76
- Quick Ratio
- 5.76
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.92
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lisata Therapeutics has paid -962.00K in taxes.
- Income Tax
- -962.00K
- Effective Tax Rate
- 0.05
Enterprise Valuation
Lisata Therapeutics EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.03.
- EV to Sales
- 3.70
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.03
- EV to Operating Cash Flow
- -0.03
Balance Sheet
Lisata Therapeutics has $10.44M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.44M billion.
- Cash & Marketable Securities
- $10.44M
- Total Debt
- $0.00
- Net Cash
- $10.44M
- Net Cash Per Share
- $0.97
- Tangible Book Value Per Share
- $0.88
Margins
Gross margin is 95.00%, with operating margin of -16427.00%, and net profit margin of -14621.00%.
- Gross Margin
- 95.00%
- Operating Margin
- -16427.00%
- Pretax Margin
- -15008.00%
- Net Profit Margin
- -14621.00%
- EBITDA Margin
- -16007.00%
- EBIT Margin
- -16071.00%
Analyst Forecast
The average price target for Lisata Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -90.65%
- EPS Growth Forecast
- 26.48%
